Review article: Role of oxidative stress in the progression of non-alcoholic steatosis

Alimentary Pharmacology and Therapeutics, Supplement

Volumn 22, Issue 2, 2005, Pages 71-73

  Albano, E ^a   Mottaran, E ^a   Occhino, G ^a   Reale, E ^a   Vidali, M ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; LIPID; MARKER;

ANTIBODY TITER; CIRCULATION; CLINICAL OBSERVATION; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MODEL; DISEASE SEVERITY; HUMAN; LIPID PEROXIDATION; LIVER CIRRHOSIS; LIVER FIBROSIS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; TITRIMETRY;

EID: 27644510537     PISSN: 09530673     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2005.02601.x     Document Type: Review

References (18)

1. Reid AE. Nonalcoholic steatohepatitis. Gastroenterology 2001; 121: 711-23.
2. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004; 114: 147-52.
3. Day CP, James OFW. Steatohepatitis: a tale of two hits? Gastroenterology 1998; 114: 842-5.
4. Weltman MD, Farrell GC, Liddle C. Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Gastroenterology 1996; 111: 1645-53.
5. Ip E, Farrell GC, Robertson G, et al. Central role of PPARα-dependent hepatic lipid turnover in dietary steatohepatitis in mice. Hepatology 2003; 38: 123-32.
6. Day CP. Non-alcoholic steatohepatitis (NASH): where are we now and where are we going? Gut 2002; 50: 585-8.
7. Seki S, Kitada T, Yamada T, et al. In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver disease. J Hepatol 2002; 37: 56-62.
8. Chalasani N, Deeg MA, Crabb DW. Systemic lipid peroxidation and its metabolic and dietary correlates in patients with non-alcoholic steatohepatitis. Am J Gastroenterol 2004; 99: 1497-502.
9. Albano E, Mottaran E, Vidali M, et al. Immune response toward lipid peroxidation products as a predictor of the progression of non-alcoholic fatty liver disease (NAFLD) to advanced fibrosis. Gut 2005; 54: 987-93.
10. Woodcroft KJ, Hafner MS, Novak RF. Insulin signalling in the transcriptional and posttranscriptional regulation of CYP2E1 expression. Hepatology 2002; 35: 263-73.
11. Weltman MD, Farrell GC, Hall P, et al. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 1998; 27: 128-33.
12. Chalasani N, Gorski JC, Asghar MS, et al. Hepatic cytochrome P4502E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. Hepatoiogy 2003; 37: 544-50.
13. Pessayre D, Mansouri A, Fromenty B. Nonalcoholic steatosis and steatohepatitis: V. Mitochondrial dysfunction in steatohepatitis. Am J Physiol 2002; 282: G193-9.
14. Fargion S, Mattioli M, Fracanzani AL, et al. Hyperferritinemia, iron overload and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis. Am J Gastroenterol 2001; 96: 2448-55.
15. Musso G, Gambino R, De Michieli F, et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatosis. Hepatology 2003; 37: 909-16.
16. Mottaran E, Stewart SF, Rolla R, et al. Lipid peroxidation contributes to immune reactions associated with alcoholic liver disease. Free Radic Biol Med 2002; 32: 38-48.
17. Stewart SF, Vidali M, Day CP, et al. Oxidative stress as a trigger for cellular immune response in patients with alcoholic liver disease. Hepatology 2004; 39: 197-203.
18. Rigamonti C, Mottaran E, Reale E, et al. Moderate alcohol consumption increases oxidative stress in patients with chronic hepatitis C. Hepatology 2003; 38: 42-9.